DIGIPHARM - an innovative solution in an important human industry!

The Digipharm PLATFORM is a single globally-sourced healthcare service platform for the public that begins with free Human Doctor-AI assisted Video Telemedicine service (Digipharm APP) already in use in 20 countries by thousands of users and an associated suite of AI assisted tools and social network for the medical community (Digipharm for Doctors).

Problem

Health care around the world do not have the relevant infrastructure to track and implement pricing that have innovative models, they are mostly reluctant to take in such policies that are innovative. Their systems are most often required to make hard decisions of whether to provide access to patients as opposed to costly pharmacological therapies while taking into cognizance their limited resources.
• Inability of patients adherence in real time
• Patients privacy
• Healthcare systems that are fragmented
• The inability to use a one size fits all customized platform that can cut across all regions
• The inconsistency in the services of healthcare providers.

DigiPharm Solution

A solution that Digipharm proposes are new methods for crowdfunding medical services that are innovative on a platform called the Evolve . They will enable this funding through initial coin offering and digital assetization to support pre-clinical studies, research, ex-vivo studies and early proof of concept research.

• Smart contracts – these are pieces of code that are self executing and facilitate, enforce or verify the conditions/terms of an agreement that has been predetermined.
• Private Channels - secure channels on the DPH private blockchain will be used to transmit sensitive data and comply with all protection and regulatory laws.
• Digital Identity Services - this will be used to create profiles for stakeholders and patients who are enrolled and still maintain their anonymity within each platform.

Digipharms’ solutions aim to accelerate the much-needed restructuring of healthcare delivery systems to a value-based approach.

---

Digipharm Platform

The refund platform uses automated "smart contracting" elements, enabling the application of a real-time model flexible pricing system and access to patients between healthcare providers, healthcare payers and information systems and administrative infrastructure involving organizations will eliminate the need for manual data handling and processing prices.Platform rebates significantly reduce operating costs associated with implementing value-based pricing systems and potentially changing drug prices and delivering health services as we know them today.The terms of the personal contracts received will be encrypted on the Reimburse platform through an accessible and automated user interface.implementation when agreement conditions are met. The replacement will also make the implementation of various conditions in the same deal price as the use of smart technology contracts, thereby providing more active and personal pricing solutions while passing through the single connection infrastructure barrier.The dynamic nature of health care and replacement systems allows manufacturers to manage and monitor their budgets more efficiently than the possibility of current comprehensive contract prices will not lead to the use or further costs incurred if a detailed deal is implemented by the current system.For example, it is possible to receive a 50% return of treatment costs after 6 months of patient survival and 75% of treatment costs ranging from 6 to 9 months and then 100% post-administration care costs, based on frequency of side effects, disease indicators and hospitalization which is slower for treatment, with additional additional management burden.

Value Based Care

Healthcare systems around the world are currently threatened by challenges unique to our time; unsustainable expenditure, ageing populations and the increasing prevalence of chronic diseases. The concept of value based healthcare proposes that payment for healthcare should be tied to the quality of care and the benefits it provides; switching from a ‘fee for service’ to a ‘fee for performance’ reimbursement model.

Innovative Pricing

Innovative pricing solutions such as value-based pricing offer an increasingly dynamic solution to address the uncertainty around the cost of treatment relative to patient outcomes. Such mechanisms reward manufacturers and providers for improving patient outcomes, incentivise innovation and encourage the transition to patient centric healthcare.

Pioneering Evidence

Innovative evidence generation solutions are necessary to satisfy the requirement of relevant, timely and quality data to inform the provision of optimised value based healthcare. Circumventing the use of static or retrospective data will open the horizon to superior forecasting, confidence in decision making and global oversight with regards to current developments in an increasingly dynamic industry such as healthcare.

Information on Digipharm token

Token Name: DPH
Total Supply: 100,000,000
Fixed (ERC-20)
Decimal: 18Pre - Sales: 15,000,000 DPH

Basic Price: 1.00 USD
Pre Sold Length: 4 Weeks
Pre-Sales Discount: 35%
Main Sales: 50.000.000 DPH

Week 1: 25% Frozen 25 million tokens
Week 2: 15% Frozen 15 million tokens
Week 3: 10% Frozen 10 million tokens
Week 4: 1.00 USD

Digipharm (DPH) tokens will be used to pay license/access fees on Digipharm platforms. Access fees will invariably be determined and stipulated in USD value and the quantity of tokens required will depend on the type of access (manufacturer, patient, payer or provider) combined with the form of interaction required. The quantity of tokens required for such interactions is subject to change, relative to the market value of DPH.

---

THE DIGIPHARM TEAM

• Ahmed Abdulla - Founder/CEO
• Girisha Fernando - Co-Founder/COO
• Zach Daniels - CTO
• Ralf Gerteis - Commercial Strategy
• Alexander Sverdlov - Cybersecurity Strategy
• Meredith Darden - Digital Marketing Lead
• Alexey Popov - Web Development
• Michael Gubert - UI/UX Design
• Leon Rebolledo - Lead Architect
• Rolf Günter - Legal Counsel
• Bobby Kaura - Business Development
• Dr. Mohamed Abdulla - Clinical Transformation
• Dr. Hasham Al-Meshhedani - Patient Engagement
• Ali Al-Sudani - Clinical Pharmacist
• Dr. Rami Radwan - Clinical Relations
• Peter Sandbach - Communications Director
• Debra De Silva-Sun - HEOR & Pricing Analyst
• Marko Granic - Graphic Designer

DIGIPHARM ADVISORS

• Sven Möller - ICO Advisor. Swisscom Blockchain AG
• Kamal Youssefi - Enterprise Blockchain Advisor. Swisscom Blockchain AG
• Waldemar Scherer - Life Sciences Blockchain Advisor. Swisscom Blockchain AG
• Sam Mantle - Health & Life Sciences Technology Advisor. Luxoft
• Daniel Heller - PR Advisor. Partner, Farner Consulting AG
• Claudio Staub - Co-Head Startup Communications. Farner Consulting AG
• Anas Aman - Quality and Testing. IBM
• Lloyd Jefferies - CRM Advisor. KPMG
• Per-Olof Thuresson - Health Economist. Roche
• Fadi Chehadah - Health Economist. NICE UK

RoadMap

More Information Connect to Digipharm
Website: https://www.digipharm.ch/
Whitepaper: https://digipharm.ch/docs/DigipharmWP.pdf
Telegram: https://t.me/joinchat/ExOHxk-TuOplQDbBWXaLaQ
Facebook: https://www.facebook.com/digipharmteam/
Twitter: https://twitter.com/DigipharmTeam

Author: https://bitcointalk.org/index.php?action=profile;u=1650071